ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Arming an Anti-CD38 Antibody With Interferon in Myeloma

James R. Berenson, MD
Published Online: 5:20 PM, Sat December 7, 2013
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.

Clinical Pearls

  • Interferon was used to treat myeloma (maintain remissions) in the 1980s and 1990s
  • When paired with interferon, this anti-CD38 agent can enhance tumor-specific activity 10,000x compared with native interferon
  • This pairing cured multiple tumors in mice
  • It remains unknown if this pairing will have effects on immune and other cells in the human body

<<< Back to the conference page



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.